BRTE yields 2000000.00% · ABBV yields 3.12%● Live data
📍 BRTE pulled ahead of the other in Year 1
Combined, BRTE + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BRTE + ABBV for your $10,000?
Brightec, Inc. engages in the development and marketing of luminescent films incorporating luminescent or phosphorescent pigments in the United States. These pigments absorb and re-emit visible light producing a glow. The company markets and sells films and consumer products, which incorporate luminescent or phosphorescent pigments and are based on its proprietary and patented technology that enables prints to be of photographic quality by day and luminescent under low light or night conditions. It offers various types of glow-in-the-dark films in sheets and rolls for commercial and digital printing needs of the graphic industry, and office and photographic digital printing market; and consumer products, including children puzzles and children stickers under the brand name PlayGlo. The company sells its luminescent product primarily as a printable luminescent film designed to add luminescence to existing and new products. It offers its product through its online store. The company was formerly known as Advanced Lumitech, Inc. and changed its name to Brightec, Inc. in October 2006. Brightec, Inc. was founded in 1992 and is based in Natick, Massachusetts.
Full BRTE Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.